We had been watching for a second Beovu label change since May 2021, when Novartis stopped three Beovu clinical trials for safety reasons, and, at the same time, said it would update the Beovu drug label. Finally, in February 2022, Novartis added information and increased safety warnings about various Beovu eye-related side effects, such as retinal … [Read more...]
Beovu Drug Label Revised December 2021 Was Issued in Europe, But Not in the US
A “new” Beovu drug label which was revised in December 2021 sets forth some additional information about the vision-related Beovu side effects intraocular inflammation, retinal vasculitis, and retinal vascular occlusion. We point out, however, that there was no similar 2021 Beovu label change issued by Novartis in the US. From this Drug Safety … [Read more...]
Beovu: Rates of Intraocular Inflammation and Retinal Vascular Occlusion
A November 2021 article published by the medical journal JAMA Ophthalmology, “Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration”, provides new information about the incidence rates of intraocular inflammation and retinal vascular occlusion associated with Beovu (brolucizumab). This is our 19th article about Beovu … [Read more...]
Drug Injury Lawsuits: List of Some Cases Filed in First Half of 2021
A drug injury lawsuit is a personal injury case or a wrongful death case involving a serious drug side effect or a severe adverse drug reaction. Here are some of the prescription medications for which drug injury lawsuits were filed against the responsible pharmaceutical company in the first half of 2021: Xeljanz Beovu Elmiron … [Read more...]
Novartis Stops 3 Beovu Clinical Trials in May 2021, Wants a Beovu Label Change
In late May 2021, the latest study data concerning Beovu safety issues resulted in Novartis stopping three key clinical trials — MERLIN, RAPTOR, and RAVEN — as well as Novartis indicating there will be another Beovu label change. To see how Novartis is seeking to present the current status of its lingering Beovu safety issues as well as the next … [Read more...]
Beovu Lawsuits Lawyer / Law Firm Handles Individuals’ Cases, Not Beovu Class Actions
We want to clear up some possible confusion. If a patient has vision loss or blindness after getting Beovu injections in their eyes, this person must contact a lawyer or law firm to handle their Beovu case in order to get legal compensation for the Beovu drug injury they have suffered. That is because Beovu lawsuits are being filed as individual … [Read more...]
Some Information About Our Monthly Law Firm Newsletter
The Lamb Law Office Newsletter is a monthly communication from our law firm to help keep you up to date with some of the cases that we are working on for clients at the present time. In addition, we provide at least one information resource item per month, which you or someone you know might find helpful from time to time. Past … [Read more...]
Beovu Side Effects and Beovu Lawsuits for Patients Complicate Future for Beovu
Given the serious nature and number of Beovu side effects reported to date, together with the Beovu lawsuits filed against Novartis for patients with severe vision loss, it seems fair to say that things look a bit grim for Beovu and Novartis at the start of 2021. So what does the path forward look like for Beovu? Let’s start with where things … [Read more...]
Beovu: What Comes Next for This Troubled Novartis AMD Eye Injection?
As we start 2021, let’s look at where things currently stand with the Beovu “safety issue” — Beovu adverse drug reactions and Beovu-related eye problems — and how we got here. In the 15 months since Beovu was approved by the FDA in October 2019, there have been numerous reports of Beovu causing occlusive retinal vasculitis, retinal artery … [Read more...]
Beovu Retinal Vasculitis Made Worse by a Later Lucentis Treatment
A recent medical journal article presents an interesting case report about a 76-year-old woman with Beovu-related retinal vasculitis which was made worse by a later Lucentis treatment for her wet AMD. That patient's doctors are the authors of "Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A … [Read more...]